Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IL1B
REST API REST API
Homo sapiens
IL1B is differentially expressed in 293 experiments: 104 organism parts: lung, blood, ... (102 more);, 140 disease states: normal, acute myeloid leukemia, ... (138 more);, 111 cell types 335 cell lines 45 compound treatments and 76 other conditions.
Synonyms IL-1B, IL1F2, IL1-BETA
Orthologs Il1b (Mus musculus)   O73909_CHICK (Gallus gallus)   il1b (Danio rerio)   Q5MAC0_BOVIN (Bos taurus)   Il1b (Rattus norvegicus)   il1b (Xenopus laevis)   IL1B_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, positive regulation of cell division, stored secretory granule, positive regulation of nitric oxide biosynthetic process, sequestering of triglyceride, elevation of cytosolic calcium ion concentration, apoptosis, vesicle, cytokine-mediated signaling pathway, ovulation, memory, negative regulation of cell proliferation, extracellular space, wound healing, positive regulation of gene expression, response to chemical stimulus, social behavior, learning or memory, growth factor activity, extracellular region, cell-cell signaling, protein domain specific binding, anti-apoptosis, response to hypoxia, cytokine activity, positive regulation of apoptosis, positive regulation of JUN kinase activity, positive regulation of JNK cascade, activation of MAPK activity, response to nutrient, positive regulation of transcription from RNA polymerase II promoter, positive regulation of histone acetylation, response to lipopolysaccharide, aging, immune response, response to drug, positive regulation of NF-kappaB transcription factor activity, regulation of I-kappaB kinase/NF-kappaB cascade, negative regulation of MAP kinase activity, response to gamma radiation, response to heat, signal transduction, negative regulation of insulin receptor signaling pathway, positive regulation of heterotypic cell-cell adhesion, positive regulation of calcidiol 1-monooxygenase activity, positive regulation of I-kappaB kinase/NF-kappaB cascade, negative regulation of adiponectin secretion, response to ozone, positive regulation of NF-kappaB import into nucleus, positive regulation of prostaglandin secretion, response to vitamin D, response to organic nitrogen, leukocyte migration, negative regulation of glutamate secretion, positive regulation of ERK1 and ERK2 cascade, cellular response to mechanical stimulus, positive regulation of stress-activated MAPK cascade, interleukin-1 receptor binding, negative regulation of lipid metabolic process, positive regulation of interleukin-2 biosynthetic process, positive regulation of T cell mediated immunity, positive regulation of chemokine biosynthetic process, response to morphine, negative regulation of lipid catabolic process, response to ATP, positive regulation of interleukin-8 production, chronic inflammatory response to antigenic stimulus, positive regulation of interferon-gamma production, positive regulation of vascular endothelial growth factor receptor signaling pathway, positive regulation of interleukin-6 production, positive regulation of histone phosphorylation, positive regulation of lipid catabolic process, response to estradiol stimulus, positive regulation of membrane protein ectodomain proteolysis, inflammatory response, positive regulation of T cell proliferation, regulation of insulin secretion, positive regulation of angiogenesis, positive regulation of interleukin-6 biosynthetic process, neutrophil chemotaxis, response to L-ascorbic acid, positive regulation vascular endothelial growth factor production, cellular response to organic substance, positive regulation of mitosis, embryo implantation, positive regulation of protein export from nucleus, response to glucocorticoid stimulus, negative regulation of glucose transport, positive regulation of protein phosphorylation, positive regulation of cell adhesion molecule production, smooth muscle adaptation, positive regulation of myosin light chain kinase activity, cellular response to drug, positive regulation of fever generation, response to organic cyclic compound, positive regulation of monocyte chemotactic protein-1 production, positive regulation of granulocyte macrophage colony-stimulating factor production, positive regulation of sequence-specific DNA binding transcription factor activity, interleukin-1 beta production
InterPro Term IL1_HBGF, IL_rcpt_IL1RA, Interleukin_1, InterleukinIL1AB, InterleukinIL1B, IL1_propep
UniProt Accession B5BUQ8, P01584, C9JSC2, C9JVK0, C9JWV2
Gene-Disease Assocation GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC
Search EB-eye ENSG00000125538
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19397, E-GEOD-2450, ... (37 experiments)

Factor Value U/D Experiments
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
SW620
2
E-MEXP-1014, E-MTAB-37
HuPT4
1
E-MTAB-37
RKO
1
E-MTAB-62
329 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-3920, E-MEXP-120, E-MEXP-750, E-GEOD-20677, ... (53 experiments)

Factor Value U/D Experiments
CD8+ T cell
4
E-AFMX-5, E-MTAB-25, E-TABM-145, E-GEOD-19069
CD4+ T cell
1
4
E-AFMX-5, E-MTAB-25, E-GEOD-16190, E-MTAB-24, E-TABM-145 ... (5 experiments)
CD105+ endothelial
1
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
105 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-25, E-GEOD-2508, E-GEOD-2466, ... (48 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-GEOD-3726, E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
obesity
2
E-GEOD-2508, E-MTAB-62
chronic myelogenous leukemia
1
2
E-MTAB-62, E-GEOD-5550, E-MTAB-37
cervical carcinoma
1
2
E-MTAB-62, E-GEOD-5823, E-MTAB-37
neuroblastoma
1
E-MTAB-62
134 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-4748, E-TABM-868, E-GEOD-3140, E-MEXP-1958, ... (30 experiments)

Factor Value U/D Experiments
lipopolysaccharide
5
E-TABM-868, E-MEXP-1958, E-GEOD-4748, E-GEOD-2706, E-GEOD-3140 ... (5 experiments)
none
5
6
E-GEOD-2706, E-MEXP-1230, E-TABM-868, E-MEXP-1958, E-GEOD-5099, ... (11 experiments)
control
1
2
E-GEOD-2638, E-GEOD-3284, E-GEOD-3004
allergen
1
E-GEOD-3004
galectin-1
1
E-GEOD-4984
baseline sevoflurane
1
E-GEOD-4386
39 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
83
2
1
E-GEOD-21653


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-3004, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-7788, E-GEOD-3325, E-GEOD-1561, E-TABM-147 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-108, E-MEXP-2340, E-MEXP-563

Genotype
studied in E-GEOD-1923, E-MEXP-149, E-GEOD-2466, E-MEXP-421, E-GEOD-22593, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5809, E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-16194, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-GEOD-1926, ... (31 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, ... (9 experiments)

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1493, E-GEOD-21750, E-GEOD-17636, E-GEOD-2487, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-18235, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16193, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-1561, E-TABM-147

Processing time: 0.333 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM